Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study

OBJECTIVES: After regulatory approval, drug companies, public funding agencies and academic researchers often pursue trials aimed at extending the uses of a new drug by testing it in new non-approved indications. Patient burden and clinical impact of such research are not well understood. DESIGN AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlisle, Benjamin Gregory, Doussau, Adélaïde, Kimmelman, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Ethics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044865/
https://www.ncbi.nlm.nih.gov/pubmed/32071183
http://dx.doi.org/10.1136/bmjopen-2019-034306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044865/
https://www.ncbi.nlm.nih.gov/pubmed/32071183
http://dx.doi.org/10.1136/bmjopen-2019-034306

Ejemplares similares